Spinal Implant Sales Make, Break Orthopedic Stocks In September
This article was originally published in The Gray Sheet
Executive Summary
Biomet's ability to beat Wall Street's first-quarter revenue estimates by roughly $9 mil. due to strong spinal implant sales drove up the company's stock 12.6% in September